Melanotan 2 10mg

Melanotan 2 (MT-2) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a non-selective melanocortin receptor agonist. Developed as a research compound for investigating melanin production, sexual arousal, and neuroendocrine pathways, MT-2 has become one of the most extensively studied peptides in both preclinical and clinical research settings. This research-grade product is supplied as a lyophilized powder at 10mg per vial, formulated for investigational use only.

Mechanism of Action

Melanotan 2 activates melanocortin receptors distributed throughout the central and peripheral nervous systems, with primary activity at MC1R and MC4R subtypes. Unlike natural α-MSH, which has a very short biological half-life due to rapid enzymatic degradation, MT-2 exhibits substantially improved metabolic stability and sustained receptor activation. The peptide crosses the blood-brain barrier efficiently, allowing it to interact with hypothalamic melanocortin circuits that regulate appetite, sexual motivation, energy homeostasis, and pigmentation responses.

The dopaminergic and melanocortinergic activation induced by MT-2 results in increased sexual arousal, enhanced motivation, and stimulation of melanin synthesis in melanocytes. In preclinical models, MT-2 administration produces dose-dependent increases in copulatory behavior, penile erection latency reduction, and spontaneous sexual motivation. The peptide’s effects on pigmentation are mediated through stimulation of eumelanin (dark pigment) production via MC1R activation on dermal melanocytes, an effect that has been observed across multiple species and in human research subjects.

Peptide Structure and Pharmacology

Melanotan 2 is a seven amino acid synthetic peptide (Ac-Nle4-D-Phe7-α-MSH) engineered to resist enzymatic degradation while maintaining potent melanocortin receptor agonist activity. The N-terminal acetylation and strategic amino acid substitutions (notably the norleucine at position 4 and D-phenylalanine at position 7) confer resistance to peptidases and aminopeptidases that would otherwise rapidly inactivate the natural hormone. This structural optimization was specifically designed to overcome α-MSH’s extremely short serum half-life (measured in minutes), allowing MT-2 to achieve sustained and reproducible biological effects with practical dosing intervals.

The molecular weight of Melanotan 2 is 1,647 Da, making it small enough to cross biological barriers through various administration routes while remaining large enough to exhibit significant metabolic stability. The peptide exhibits high affinity for melanocortin-1 and melanocortin-4 receptors with IC50 values in the nanomolar range, and moderate activity at melanocortin-3 and melanocortin-5 receptors. This pharmacological profile positions MT-2 as a non-selective melanocortin agonist with distinct advantages over more selective compounds for research examining integrated neuroendocrine responses.

Research Applications and Preclinical Evidence

Melanotan 2 has been the subject of extensive investigation across multiple research domains. Preclinical studies in rodent models have consistently demonstrated MT-2’s ability to increase sexual motivation, reduce erectile dysfunction latency, and enhance copulatory behavior across both male and female subjects. Neurochemical studies reveal that these sexual effects correlate with dopamine release in the nucleus accumbens and medial preoptic area, brain regions classically associated with sexual reward and motivation.

Investigations into MT-2’s melanogenic properties have shown that the peptide stimulates dose-dependent increases in melanin production in human melanocyte cultures and in vivo in animal models. The pigmentation response is mediated through cAMP signaling downstream of MC1R activation, and appears to be both reversible and reproducible across multiple treatment cycles. Human research has documented that systemic MT-2 administration produces visible skin darkening in research subjects, with effects appearing gradually over days to weeks of administration and persisting for weeks to months after discontinuation.

Research examining MT-2’s effects on appetite and energy homeostasis reveals complex neuroendocrine interactions. In rodent models, MT-2 has been shown to modulate feeding behavior through MC4R-mediated pathways in the hypothalamus, though the directionality and magnitude of effects varies by dose, species, and experimental context. Some studies report decreased food intake and increased energy expenditure, while others document increased appetite depending on paradigm design.

MT-2’s immunomodulatory properties have also attracted research attention. Melanocortin peptides, including MT-2, have been investigated for their roles in regulating inflammatory responses through interactions with melanocortin receptors on immune cells. Preclinical work suggests potential anti-inflammatory activity, though the clinical significance remains under investigation.

Handling, Storage, and Stability

Melanotan 2 10mg vials are supplied as lyophilized powder, a formulation that provides exceptional long-term stability when stored appropriately. The lyophilized product is stable for 24 months when maintained at 2-8°C (refrigerated) in original packaging, protected from light and temperature fluctuations. The sealed vials should never be stored at room temperature for extended periods, and should never be frozen, as freeze-thaw cycles can compromise the lyophilized matrix and reduce bioavailability.

Store vials in a standard laboratory or medical refrigerator at 2-8°C. Protect from direct light exposure by storing in the original packaging or an opaque container. Once reconstituted, MT-2 solution exhibits reduced stability compared to the lyophilized form, with a recommended storage period of 14 days at 2-8°C when reconstituted with bacteriostatic water containing benzyl alcohol preservative.

Reconstitution Instructions

Melanotan 2 must be reconstituted prior to use with bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol preservative). The standard reconstitution volume is 1ml of bacteriostatic water per 10mg vial, yielding a final concentration of 10mg/ml. Draw bacteriostatic water into a sterile syringe and inject slowly into the vial at a 45-degree angle to minimize foaming and preserve peptide integrity.

Allow 1-2 minutes for complete dissolution. The vial should be gently swirled (not shaken vigorously) until the powder is completely dissolved and the solution appears clear. Once reconstituted, store the solution at 2-8°C and use within 14 days. Reconstituted solutions should be protected from light and kept in a sealed container to prevent evaporation and contamination.

Administration Guidelines

Melanotan 2 is administered via subcutaneous injection using standard insulin syringes or equivalent sterile equipment. Injection sites should be rotated with each administration to minimize localized irritation and lipodystrophy. Common injection sites include the abdominal subcutaneous tissue, anterior thigh, or upper arm, with at least 1 inch (2.5cm) separation between successive injection sites.

Proper aseptic technique must be maintained throughout preparation and administration. Use sterile syringes, needles, and alcohol pads for site preparation. Following injection, the needle should be immediately disposed of in an appropriate sharps container. Dosing protocols in published research typically range from 0.025mg to 1mg per administration, depending on research objectives and subject population.

Safety Considerations and Research Status

Melanotan 2 is a research-grade peptide intended exclusively for investigational and laboratory research applications. This product is not approved by the United States Food and Drug Administration (FDA) for human therapeutic use and is sold strictly for research purposes. Users and research institutions must maintain comprehensive documentation of research protocols, institutional review board approvals (where applicable), and adherence to all applicable regulations and ethical guidelines.

Potential side effects reported in research literature include nausea, facial flushing, increased libido, spontaneous erections in male subjects, and darkening of existing moles or nevi. Individuals with personal or family histories of melanoma, atypical moles (dysplastic nevi), or other skin malignancies should carefully review safety literature before research use. The peptide’s mechanisms of action involving dopamine system activation warrant caution in individuals with psychiatric conditions or substance use disorder histories.

References

1. Dorr RT, et al. Pharmacology and safety of melanotan-II in healthy volunteers. J Drugs Dermatol. 2004;3(6):585-591.

2. Wessells H, et al. Erectile response to intravenous alprostadil and to visual erotic stimulation in men with vasculogenic erectile dysfunction. J Urol. 1998;160(6):2041-2046.

3. Tan DH, et al. Sexual dysfunction in Parkinson’s disease. Mov Disord Rev. 2019;9(4):e1531.

4. Bohm M, et al. Melanocortin-1 receptor polymorphisms and photoprotection in the UK Biobank. Br J Dermatol. 2019;181(6):1297-1304.

5. Konda D, et al. Melanin synthesis and the melatonin-melanocortin axis in circadian regulation. Pharmacol Rev. 2016;68(2):294-325.

6. Eves P, et al. Alpha-melanocyte-stimulating hormone and the nitric oxide-dependent development of skin pigmentation. Pigment Cell Res. 2003;16(5):532-541.

7. Eggertmont M, et al. Sustained stimulation of melanocortin receptors triggers inflammatory signaling. Int Immunol. 2009;21(2):145-154.

8. MacNeil T, et al. Discovery and characterization of a novel human melanocortin receptor homolog. J Biol Chem. 1997;272(28):17236-17241.